Stock APGE APOGEE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Apogee Therapeutics, Inc.

Equities

APGE

US03770N1019

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
46.04 USD -3.82% Intraday chart for Apogee Therapeutics, Inc. -14.34% +64.78%
May. 15 Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases CI
May. 13 Apogee Therapeutics' Q1 Net Loss Widens MT

Evolution of the average Target Price on Apogee Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

e317171d3a83affcfbe76c52e9a7.mzLf-vHYtdG0krsNkA_atxSx9CO2OX294xVppAv7gic.z32Jy5Kd7KPk-8x92kSi20uIjFvEVjPrriIA70-u6mzsW--su-DHm_7Z3A~ec2f770e70d6d8032d987bd74c71cc0d

Analyst Recommendations on Apogee Therapeutics, Inc.

BofA Securities Starts Coverage on Apogee Therapeutics With Buy Rating, $80 Price Target MT
Jefferies Adjusts Price Target on Apogee Therapeutics to $75 From $37, Maintains Buy Rating MT
Wedbush Raises Apogee Therapeutics' PT to $87 From $40 After Reporting Initial Safety, PK Results From Phase 1 Trial of APG777; Maintains Outperform Rating MT
Guggenheim Adjusts Apogee Therapeutics' Price Target to $44 From $29, Maintains Buy Rating MT
BTIG Initiates Apogee Therapeutics With Buy Rating, Price Target is $43 MT
TD Cowen Initiates Apogee Therapeutics With Outperform Rating MT
Stifel Initiates Apogee Therapeutics With Buy Rating, $34 Price Target MT
Jefferies Initiates Apogee Therapeutics With Buy Rating, $29 Price Target MT
Guggenheim Starts Apogee Therapeutics With Buy Rating, $29 Price Target MT
Wedbush Initiates Apogee Therapeutics at Outperform With $40 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
46.04 USD
Average target price
84.83 USD
Spread / Average Target
+84.26%
High Price Target
95 USD
Spread / Highest target
+106.34%
Low Price Target
75 USD
Spread / Lowest Target
+62.90%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Apogee Therapeutics, Inc.

BofA Securities
Jefferies & Co.
Wedbush
Guggenheim
BTIG
TD Cowen
Stifel Nicolaus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. APGE Stock
  4. Consensus Apogee Therapeutics, Inc.